Reports Q3 revenue $13.62M, consensus $5.56M. "Harpoon continues to advance its next-generation T cell engagers to address a broad patient population with unmet needs in both solid tumor and blood cancer indications," said Julie Eastland, president and CEO of Harpoon Therapeutics. "We have made the decision to fully focus our resources on our collaborations and the clinical development of HPN217 targeting BCMA, HPN328 targeting DLL3 and HPN601 targeting EpCAM, all of which are in or nearing the clinic. As a result, we will be reducing our workforce by approximately 45%, primarily research and supportive functions."
Published first on TheFly
Read More on HARP:
- Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition
- Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer
- Harpoon Therapeutics appoints Luke Walker as Chief Medical Officer
- Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors